ECM
ALNY icon

Everence Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Everence Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$983K Hold
2,970
– – 0.06% 240
2025
Q4 		$1.18M Hold
2,970
– – 0.07% 215
2025
Q3 		$1.35M Hold
2,970
– – 0.08% 195
2025
Q2 		$968K Hold
2,970
– – 0.06% 235
2025
Q1 		$802K Buy
2,970
+450
+18% +$116K 0.05% 269
2024
Q4 		$593K Buy
+2,520
New +$663K 0.04% 317

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Everence Capital Management's ALNY Position: Q1 2026 in Review

Everence Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 2,970 shares worth $983K. The position accounts for 0.06% of the portfolio, ranked #240.

Everence Capital Management first reported a position in ALNY in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.35M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Everence Capital Management held 2,970 shares of Alnylam Pharmaceuticals worth $983K as of Q1 2026.
  • Everence Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.06% of Everence Capital Management's portfolio in Q1 2026, its #240 holding.
  • Everence Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Everence Capital Management's Alnylam Pharmaceuticals position peaked at $1.35M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.